March 22, 2024Cancer Research

In Situ CAR T Cell Engineering Using Targeted Lipid Nanoparticles for Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

NZNisi ZhangPalo Alto University ERElise RobinsonBroad Institute ARAngelie Rivera‐RodriguezStanford Medicine

Discussion

Member takes

Implication

Preclinical study demonstrates in situ CAR T cell generation using targeted lipid nanoparticles in murine lymphoma, indicating potential to bypass complex ex vivo cell manufacturing.

Key Points

In situ chimeric antigen receptor generation via targeted lipid nanoparticles successfully reprogrammed host T cells, stimulating robust antitumor immune cell infiltration.
Engineered anti cd5 formulations achieved binding in 65.2% of T cells and induced CAR expression in 11.64% of cells, exceeding non-treated and IgG controls.
Flow cytometry and bioluminescence imaging confirmed targeted delivery across lymphoid organs; mouse model, further preclinical work needed before human translation.

Cite This Study

Zhang et al. (2024) studied this question.

synapsesocial.com/papers/68e72f4bb6db6435876a87aa https://doi.org/10.1158/1538-7445.am2024-35

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study demonstrates in situ CAR T cell generation using targeted lipid nanoparticles in murine lymphoma, indicating potential to bypass complex ex vivo cell manufacturing.

In Situ CAR T Cell Engineering Using Targeted Lipid Nanoparticles for Lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

In Situ CAR T Cell Engineering Using Targeted Lipid Nanoparticles for Lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider